AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

ALTANA Pharma AG develops and manufactures pharmaceuticals. It provides services in the areas of therapeutics, imaging and OTC medication. The company is headquartered in Konstanz, Germany.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a company headquartered in Konstanz, Germany, that manufactures pharmaceutical products. The firm was founded in 1873. Wolfgang Eck, Uwe Hoffmeister and Roland Kurney are the current co-CEOs of the company.

Part of GSK Plc, Beecham Group Plc is a British company located in Middlesex. The firm functions as an investment holding company. It was founded in 1928.\nThe company says this about itself: The principal activity Of the Company is the holding of Intercompany bans and receipt Of interest. The Company had previously been an investment holding company. The Company is a member Of the GlaxoSmithKline Group (the 'Group\"). The directors do not envisage any change to the nature of the business in the future,

Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

MEDA Pharma is a company that provides healthcare services to people of high quality with safety. A medium-sized pharmaceutical company, Madaus GmbH belongs to the worldwide operating Meda Group. They manufacture pharmaceuticals as well as scientifically based health products such as medical devices, cosmetics, and dietary supplements. Its mission was to set new standards for health care, give 7 billion people access to high-quality medicine, and carry out research to address unmet healthcare needs.

Indena is the world’s leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research) and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. It engages in the manufacture of new medicines and medical substances as well as the sale of healthy food. It operates through the Natural and Bio Substance business divisions. The company was founded by Sun-Young Kim on November 21, 1996 and is headquartered in Seoul, South Korea.

Boehringer Ingelheim Corporate Center GmbH, part of C.H. Boehringer Sohn AG & Co. KG, is a company headquartered in Ingelheim am Rhein, Germany. The firm leases real estate properties. It was founded in 2016.

Korea Food Research Institute is a global food R&D institution that contributes to the health of Korea.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing with new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

EpiEndo Pharmaceuticals ehf is an Icelandic company located in Seltjarnarnes that develops chronic respiratory diseases. The firm was founded in 2014 by Fridrik Gardarsson. Maria Bech has been the CEO since 2021.\nThe company says this about itself: EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases. EpiEndo is developing a proprietary portfolio of macrolide drugs, whilst avoiding bacterial resistance, called Barriolides, with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is significant unmet medical need. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral macrolide which avoids bacterial resistance, is barrier strengthening and anti-inflammatory for the treatment of COPD.